# Nxera has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company.

*biotech · news · 2026-04-08 · The Manila Times*

## Key points

- Nxera achieved a second development milestone in its collaboration with Eli Lilly for diabetes drugs.
- The milestone validates Nxera’s NxWave platform for identifying small molecule binders to GPCR targets.
- Lilly will now take over further development and commercialization of the identified drug candidates.
- Nxera is eligible for up to US$694 million in milestones plus tiered royalties under the agreement.

**Companies:** Eli Lilly and Company, Nxera Pharma Co., Ltd.
**Countries:** Japan, UK, Switzerland, South Korea

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/09/tmt-newswire/globenewswire/nxera-pharma-achieves-second-development-milestone-in-collaboration-with-eli-lilly-targeting-metabolic-diseases/2316872)

---

Canonical: https://newsio.io/n/93b5ce5c-3254-40bf-ace8-ac22c57cb87e/nxera-has-achieved-a-second-development-milestone-under-its-multi-target-collabo
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works